BIB vs. AMGN

Last updated Apr 2, 2026

Compare and contrast key facts about ProShares Ultra Nasdaq Biotechnology (BIB) and Amgen Inc. (AMGN).

BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010.

Performance

BIB vs. AMGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ProShares Ultra Nasdaq Biotechnology (BIB) and Amgen Inc. (AMGN). The values are adjusted to include any dividend payments, if applicable.

BIB vs. AMGN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BIB ProShares Ultra Nasdaq Biotechnology	3.51%	59.21%	-9.84%	-1.06%	-28.85%	-6.02%	39.79%	46.71%	-24.93%	40.49%
AMGN Amgen Inc.	8.68%	29.67%	-6.77%	13.46%	20.43%	0.87%	-1.99%	27.60%	15.23%	22.27%

Returns By Period

In the year-to-date period, BIB achieves a 3.51% return, which is significantly lower than AMGN's 8.68% return. Over the past 10 years, BIB has underperformed AMGN with an annualized return of 6.98%, while AMGN has yielded a comparatively higher 11.92% annualized return.

BIB

• 1D: 1.31%
• 1M: -5.43%
• YTD: 3.51%
• 6M: 32.05%
• 1Y: 82.75%
• 3Y*: 16.12%
• 5Y*: 0.02%
• 10Y*: 6.98%

AMGN

• 1D: 0.41%
• 1M: -8.41%
• YTD: 8.68%
• 6M: 20.02%
• 1Y: 18.72%
• 3Y*: 17.09%
• 5Y*: 10.65%
• 10Y*: 11.92%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BIB vs. AMGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BIB

BIB Risk / Return Rank: 85
BIB Sharpe Ratio Rank: 85
BIB Sortino Ratio Rank: 83
BIB Omega Ratio Rank: 74
BIB Calmar Ratio Rank: 91
BIB Martin Ratio Rank: 89

AMGN

AMGN Risk / Return Rank: 61
AMGN Sharpe Ratio Rank: 64
AMGN Sortino Ratio Rank: 58
AMGN Omega Ratio Rank: 55
AMGN Calmar Ratio Rank: 64
AMGN Martin Ratio Rank: 65

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BIB vs. AMGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and Amgen Inc. (AMGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BIB	AMGN	Difference
Sharpe ratio Return per unit of total volatility	1.78	0.65	+1.13
Sortino ratio Return per unit of downside risk	2.29	1.13	+1.15
Omega ratio Gain probability vs. loss probability	1.29	1.14	+0.15
Calmar ratio Return relative to maximum drawdown	3.35	1.10	+2.25
Martin ratio Return relative to average drawdown	11.88	2.67	+9.21
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BIB vs. AMGN - Sharpe Ratio Comparison

The current BIB Sharpe Ratio is 1.78, which is higher than the AMGN Sharpe Ratio of 0.65. The chart below compares the historical Sharpe Ratios of BIB and AMGN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BIB	AMGN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.78	0.65	+1.13
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.00	0.45	-0.45
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.15	0.48	-0.33
Sharpe Ratio (All Time) Calculated using the full available price history	0.35	0.61	-0.27

Correlation

The correlation between BIB and AMGN is 0.65, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

BIB vs. AMGN - Dividend Comparison

BIB's dividend yield for the trailing twelve months is around 0.60%, less than AMGN's 2.73% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BIB ProShares Ultra Nasdaq Biotechnology	0.60%	0.77%	1.69%	0.07%	0.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
AMGN Amgen Inc.	2.73%	2.91%	3.45%	2.96%	2.95%	3.13%	2.78%	2.41%	2.71%	2.65%	2.74%	1.95%

Drawdowns

BIB vs. AMGN - Drawdown Comparison

The maximum BIB drawdown since its inception was -67.24%, which is greater than AMGN's maximum drawdown of -63.48%. Use the drawdown chart below to compare losses from any high point for BIB and AMGN.

Drawdown Indicators

	BIB	AMGN	Difference
Max Drawdown Largest peak-to-trough decline	-67.24%	-63.48%	-3.76%
Max Drawdown (1Y) Largest decline over 1 year	-21.73%	-15.35%	-6.38%
Max Drawdown (5Y) Largest decline over 5 years	-65.86%	-24.86%	-41.00%
Max Drawdown (10Y) Largest decline over 10 years	-66.20%	-24.86%	-41.34%
Current Drawdown Current decline from peak	-23.89%	-8.99%	-14.90%
Average Drawdown Average peak-to-trough decline	-32.84%	-16.80%	-16.04%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.13%	6.36%	-0.23%

Volatility

BIB vs. AMGN - Volatility Comparison

ProShares Ultra Nasdaq Biotechnology (BIB) has a higher volatility of 16.73% compared to Amgen Inc. (AMGN) at 6.09%. This indicates that BIB's price experiences larger fluctuations and is considered to be riskier than AMGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BIB	AMGN	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.73%	6.09%	+10.64%
Volatility (6M) Calculated over the trailing 6-month period	28.82%	20.41%	+8.41%
Volatility (1Y) Calculated over the trailing 1-year period	47.20%	28.98%	+18.22%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	43.32%	23.87%	+19.45%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	46.77%	24.73%	+22.04%